SEC Company Response from EXAGEN INC. (XGN) (CIK 0001274737) (XGN) — Sep 16, 2019
EXAGEN INC. (XGN) (CIK 0001274737)
Date: Sept. 16, 2019 · CIK: 0001274737 · Accession: 0001193125-19-245830
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233446
Letter
VIA EDGAR Division of Corporation Finance Washington, D.C. 20549 Re: Exagen Inc. Registration Statement on Form S-1 File No. 333-233446
Dear Mr. Lopez:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Exagen Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on September 18, 2019, or as soon as practicable thereafter.
The undersigned, on behalf of the Company, acknowledges the following:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact Jeffrey Woodley of Latham & Watkins LLP, counsel to the Company, at (858) 523-5464, or in his absence, Matthew T. Bush at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
Very truly yours,
EXAGEN INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Exagen Inc. 1261 Liberty Way, Suite C Vista, CA 92081 September 16, 2019 VIA EDGAR John Reynolds Assistant Director Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Exagen Inc. Registration Statement on Form S-1 File No. 333-233446 Dear Mr. Lopez: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Exagen Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on September 18, 2019, or as soon as practicable thereafter. The undersigned, on behalf of the Company, acknowledges the following: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please contact Jeffrey Woodley of Latham & Watkins LLP, counsel to the Company, at (858) 523-5464, or in his absence, Matthew T. Bush at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter. Very truly yours, EXAGEN INC. By: /s/ Fortunato Ron Rocca Fortunato Ron Rocca President, Chief Executive Officer and Director cc: Ruairi Regan, Securities and Exchange Commission Joanna Lam, Securities and Exchange Commission Raj Rajan, Securities and Exchange Commission Brigitte Lippman, Securities and Exchange Commission Pam Howell, Securities and Exchange Commission Fortunato Ron Rocca, Exagen Inc. Cheston J. Larson, Latham & Watkins LLP Matthew T. Bush, Latham & Watkins LLP